Complete Conference Coverage Archive
Reducing the duration of androgen-deprivation therapy with radiation therapy from 36 months to 18 months is safe for patients with high-risk prostate cancer.
Patients with early stage, HER2-negative breast cancer may be sufficiently well-treated with docetaxel and cyclophosphamide instead of anthracycline-based chemotherapy.
Don Dizon, MD: In addition to important clinical trial outcomes that evaluated novel strategies across tumor types, there were impressive studies aiming to help our patients live with cancer as well.
An automated bone scan index at baseline is clinically validated as a prognostic biomarker in men with castration-resistant prostate with bone metastases.
Only 21% of patients underwent IGHV mutation-testing prior to initiating bendamustine plus rituximab therapy; 46% of tested patients were IGHV-mutated.
In this question-and-answer session, Cancer Therapy Advisor asked Dr Duma about her team's study and minority patient representation in breast cancer studies.
Bevacizumab added to a standard platinum doublet chemotherapy regimen did not improve OS, though PFS was improved, among patients with cancer of the head and neck.
Study data suggest that some women with breast cancer may benefit from intermittent over continuous letrozole treatment.
Perioperative FLOT significantly improved PFS and OS among patients with resectable gastric cancers compared with standard ECF/ECX.
Pembrolizumab monotherapy showed clinical efficacy in patients with advanced gastric cancer.
Ulka Vaishampayan, MD, and Neeraj Agarwal, MD, spoke with Cancer Therapy Advisor about treatment recommendations for patients newly diagnosed with metastatic RCC.
Nivolumab alone or combined with ipilimumab provided durable responses in patients with advanced small-cell lung cancer whose disease progressed on prior platinum therapies.
Data from the BFORE study showed significantly higher 12-month major molecular remission and complete cytogenetic response with bosutinib.
For patients with primary or secondary myelofibrosis who have already received ruxolitinib, momelotinib was significant in improving disease-related symptoms over best available therapy.
Patients with BRAF V600E melanoma and brain metastasis showed intracranial responses when receiving a BRAF (dabrafenib) and a MEK inhibitor (trametinib).
Veliparib added to cisplatin and etoposide improves progression-free survival among patients with extensive stage small-cell lung cancer.
An analysis suggested that a shorter, 3-month course of adjuvant chemotherapy for some patients with stage III colon cancer may yield comparable outcomes to the standard 6-month course.
Patients with a germline BRCA mutation were at a reduced risk for progression when treated with olaparib for HER2-metastatic breast cancer.
Nivolumab With Ipilimumab May Negate Need for Whole Brain Radiotherapy in Melanoma With Brain Metastases
Combination immunotherapy with nivolumab and ipilimumab provided intracranial and extracranial responses for patients with melanoma and brain metastases.
Nivolumab alone or in combination with ipilimumab were reported to show activity in patients with melanoma and asymptomatic brain metastases.
After looking at 8 short-term endpoints based on PSA and CTCs, absence of tumor cells at week 13 was considered the best predictor of overall survival.
When combined with an aromatase inhibitor, dual HER2 blockade shows superior PFS compared with lapatinib or trastuzumab alone in some women with breast cancer.
The antibody drug conjugate, T-DM1, when used alone or in combination with pertuzumab, did not significantly improve overall survival compared with trastuzumab and a taxane.
Evidence suggests that combining palbociclib with endocrine therapy can reverse acquired resistance to endocrine therapy in breast cancer.
A study showed that symptom monitoring by integrating electronic patient-reported outcomes into clinical practice vs usual care extended OS by more than 5 months.
Data from PALOMA-1/TRIO-18 showed that combining palbociclib and letrozole did not significantly improve survival compared with letrozole alone among patients with breast cancer.
Patients with breast cancer who progress on endocrine therapy and are then treated with abemaciclib and fulvestrant have a 45% decreased risk for progression.
Vemurafenib improves outcomes among patients with non-small cell lung cancer with a BRAFV600 mutation.
Aldoxorubicin significantly prolongs PFS and provides better objective response rates than investigators' choice of treatment or standard of care in the treatment of soft tissue sarcoma.
Consuming Korean red ginseng was reported to improve cancer-related fatigue among Korean patients with colorectal cancer (CRC) treated with FOLFOX.
Nivolumab, a programmed death (PD)-1 inhibitor, showed promising clinical activity in recurrent or metastatic cervical cancers and provides a promising new approach to treatment.
A retrospective analysis of next-generation sequencing profiles has diagnostic and therapeutic implications for patients with soft-tissue or bone sarcoma.
The landscape of complex genetic mutations in sarcomas seen through next-generation sequence profiling provides a rationale for a study to match patients to the appropriate therapy.
A study concluded that adjuvant therapy with a taxane and a platinum agent was not superior over standard therapy for women with high-risk endometrial cancer.
Improvements in cancer-related fatigue from yoga were linked to improvements in sleep quality and daytime dysfunction.
Toxicity-driven dosing of sunitinib improved response rates and survival compared with historical standard dosing among patients with metastatic renal cell carcinoma.
Patients with a decline in HGF levels had longer overall survival than those with high levels at baseline and at 4 weeks.
A modified dosing schedule of sunitinib did not improve adverse events rates among patients with metastatic renal cell carcinoma.
Pembrolizumab shows antitumor activity in osteosarcoma and undifferentiated pleomorphic sarcoma, but not other types of soft tissue sarcomas.
Cabozantinib may have activity in carcinosarcoma and warrants further investigation.
Patients with Ewing sarcoma aged 19 to 39 years may benefit from treatment at a specialized cancer center.
Patients with chronic lymphocytic leukemia younger than age 55 are at an increased risk for multiple types of secondary cancers for up to 15 years after diagnosis.
Ibrutinib provides long term survival benefits to patients with chronic lymphocytic leukemia regardless of cytogenetic risk factors.
Fludarabine and rituximab plus lenalidomide results in durable prolonged PFS compared with FR or FR plus cyclophosphamide among patients with untreated chronic lymphocytic leukemia.
Data suggest that cediranib-treatment of ASPS results in a substantial reduction in tumor burden and prolonged PFS.
SARC024 study met its primary endpoint for patients with Ewing sarcoma, and enrollment is ongoing for the liposarcoma and osteosarcoma cohorts.
Pazopanib showed antitumor efficacy among patients with unresectable or metastatic malignant/dedifferentiated soft fibrous tumors.
The US Affordable Care Act may have increased the proportion of patients with cancer diagnosed at stage I, according to a study.
Adjuvant gefitinib significantly prolongs disease-free survival compared with vinorelbine plus cisplatin among patients with stage II to III non-small cell lung cancer.
Interprofessional practice provides benefits to patients, team members, and the health care system, by working collaboratively to support and assist each other.
This study suggest that nilotinib is associated with higher rates of treatment-induced T2DM and hyperlipidemia compared with dasatinib.
This study indicates that there is no difference in efficacy or safety between aprepitant and fosaprepitant, though the study was limited by its small sample size.
Oncology clinicians face ethical dilemmas regarding access to care and treatments, palliative and end-of-life care, and treating vulnerable populations in today's clinical environment.
Four new agents were approved for relapsed/refractory multiple myeloma (RRMM) since 2015, providing more options but adding complexity to the treatment of this disease.
Lanreotide depot is effective among patients with or without previous octreotide treatment for carcinoid syndrome.
Two SNPS (rs4880 and rs1870377) had an association with PFS among patients with DLBCL receiving R-CHOP.
Glucocorticoid-containing chemotherapy may induce diabetes mellitus or worsen glucose control among patients with diffuse large B cell lymphoma.
At the 2017 HOPA Annual Conference, Vivian Park, PharmD, MBA, BCOP, discussed agents approved by the FDA in oncology in 2016.
Multiple value frameworks were developed to help providers, institutions, and payers determine the value of cancer treatment.
In an indirect comparison, brigatinib appeared to have greater efficacy than alectinib or ceritinib in ALK+ non-small cell lung cancer.
A study suggests that single-agent ibrutinib results in durable responses among patients with CLL or SLL.
Data suggest that most patients with MM taking immunomodulatory therapy are not receiving appropriate thromboprophylaxis.
The findings of this study suggest that leflunomide may be an effective treatment of CMV infection among patients who have received allo-HSCT.
Data suggest that off-label prescribing may increase the time to treatment receipt, but may lower costs for patients.
Hypermethylation of HRR-associated genes was not associated with improved survival in ovarian cancer.
Study data suggest that SLN mapping is more cost-effective and more efficacious than routine LND or selective LND.
Study results suggest that carefully selected elderly patients with recurrent or refractory gynecologic malignancy should be enrolled in phase 1 trials.
Patients with newly diagnosed ovarian cancer rank nausea as the most concerning side effect associated with chemotherapy.
Combined liquid-based Pap and CT-DNA may be a new method for tumor-derived driver mutation screening in primary ovarian carcinoma.
The results of this study show that implementation of strategies to reduce SSI can improve SSI rates, despite risk factors for infection.
Adjuvant platinum-based chemotherapy did not improve survival in women with low-grade serous ovarian cancer.
Data suggest that adjuvant chemotherapy without radiation may be an effective option for patients with stage IB to IIA cervical cancer with risk factors.
Data indicate that the addition of WPR to chemotherapy may provide a survival benefit, though prospective studies are needed to confirm these findings.
Study results suggest that aggressive molecular subtypes of endometrial cancer are more common among the African American population.
Gynecologic oncologists are at a particularly high risk for burnout compared with other specialties, suggesting a need for burnout prevention and wellness programs.
The Hospital Readmission Reduction Program may unfairly penalize hospitals if 30-day readmission rates are the only metric for care quality.
Patients with endometrial cancer who have isolated tumor cells identified by sentinel lymph node mapping should not routinely receive adjuvant chemotherapy.
BRCA1 and RAD51C methylation in ovarian carcinomas are associated with sensitivity to PARP inhibitors, such as rucaparib.
Sentinel lymph node biopsy was associated with fewer surgical complications, less lymphedema, and better quality of life.
Physicians will speak about tumor evolution and AR-indifferent disease at the 2017 ASCO Genitourinary Cancers Symposium in Orlando, Florida.
Patients with metastatic renal carcinoma (mRCC) treated with post-frontline agents had increased genomic alterations.
Bleomycin, etoposide, and cisplatin (BEP) for 1 cycle after orchiectomy is associated with a similar 2-year recurrence rate as BEP.
Studies presented in the last year demonstrated a revolutionary role for immune checkpoint inhibitors.
Pembrolizumab following platinum-based chemotherapy was associated with significantly longer overall survival, fewer adverse events.
David J. McConkey, MD, PhD, described how genomics can affect the clinical management of patients with bladder cancer.
The clinical outcomes when using neoadjuvant chemotherapy for muscle-invasive bladder cancer vary by molecular subtype.
Adding chemotherapy with fluorouracil and mitomycin to radiotherapy improves locoregional control.
Full-length androgen receptor (AR-FL) copy number derived from circulating tumor cells detected using a liquid biopsy.
At a general session at the 2017 ASCO GU Symposium, the latest advances in managing SRMs will be discussed.
A phase 3 study presented at the 2017 Genitourinary Cancers Symposium demonstrated the feasibility of conducting adjuvant trials.
Researchers identified nearly 80 significantly mutated genes in prostate cancer, including many novel genes and pathways.
The Decipher genomic classifier obtained from biopsy samples was prognostic for distant metastases and prostate cancer-specific mortality.
Despite early failures, there may be a role for single-agent and combination immunotherapy for patients with prostate cancer.
The risk for developing prostate cancer is more than 5 times higher for men in the top 1% of the genetic risk score group.
At an education session at the 2017 GU Symposium experts will discuss some of the barriers to progress in the treatment of bladder cancer.
Patients with advanced renal cell carcinoma (RCC) who discontinued anti-PD-1/PD-L1 immunotherapy early may still achieve durable responses.
A higher overall number of genetic alterations in cell-free circulating tumor DNA (ctDNA) were associated with worse treatment outcomes.
Patients with advanced kidney cancer received broad-spectrum antibiotics less than a month before initiating immune checkpoint inhibitor therapy.
Thyroid cancer survivors diagnosed prior to age 40 have an increased risk of developing diseases associated with aging.
About 4 in 10 partners of young breast cancer survivors experience anxiety.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Low-fat Diet and Breast Cancer
- The Adverse Effects of Sarcoma Treatment in Cancer Survivors
- Some Patients With Terminal Cancer Receive Unnecessary Aggressive Treatment
- Anti-CD19 CAR-T Cells May Be Safe and Effective in Chronic Lymphocytic Leukemia
- Active Surveillance and Watchful Waiting for Low-risk Prostate Cancer
- Weight in Adolescence May Predict Colorectal Cancer Risk
- Haploidentical Transplantation Effective as Front-line Therapy for Standard-risk ALL
- Ipilimumab Indication Expanded To Include Pediatric Unresectable or Metastatic Melanoma
- Immune-mediated Hepatitis: Challenges in Management
- Phase 1 Study of A Dendritic Cell Vaccine for High-grade Glioma and Glioblastoma